Capecitabine News and Research

RSS
Keryx does not meet primary endpoint in perifosine + capecitabine Phase 3 trial for colorectal cancer

Keryx does not meet primary endpoint in perifosine + capecitabine Phase 3 trial for colorectal cancer

Aeterna Zentaris X-PECT Phase 3 refractory advanced colorectal cancer trial fails to meet primary endpoint

Aeterna Zentaris X-PECT Phase 3 refractory advanced colorectal cancer trial fails to meet primary endpoint

Positive results from Genentech's T-DM1 Phase III trial on HER2-positive mBC

Positive results from Genentech's T-DM1 Phase III trial on HER2-positive mBC

FDA accepts Genentech's pertuzumab BLA and grants Priority Review

FDA accepts Genentech's pertuzumab BLA and grants Priority Review

Yakult Honsha commences perifosine Phase 1/2 trial for refractory advanced colorectal cancer in Japan

Yakult Honsha commences perifosine Phase 1/2 trial for refractory advanced colorectal cancer in Japan

Positive results from Puma's neratinib Phase II trials presented at CTRC-AACR San Antonio Breast Cancer Symposium

Positive results from Puma's neratinib Phase II trials presented at CTRC-AACR San Antonio Breast Cancer Symposium

Positive results from Genentech's pertuzumab plus Herceptin Phase III study on HER2-positive mBC

Positive results from Genentech's pertuzumab plus Herceptin Phase III study on HER2-positive mBC

Conference highlights advances in evidence-based integrative therapies for cancer

Conference highlights advances in evidence-based integrative therapies for cancer

Genentech announces results of trastuzumab emtansine Phase II study on HER2-positive mBC

Genentech announces results of trastuzumab emtansine Phase II study on HER2-positive mBC

Hoffman La Roche, Mylan enter settlement and license agreement for XELODA Tablets

Hoffman La Roche, Mylan enter settlement and license agreement for XELODA Tablets

Nektar announces positive results from NKTR-102 Phase 2 study on metastatic breast cancer

Nektar announces positive results from NKTR-102 Phase 2 study on metastatic breast cancer

Avastin increases tumor response rates in breast cancer patients before surgery

Avastin increases tumor response rates in breast cancer patients before surgery

Recruitment complete in Aeterna Zentaris' perifosine Phase 3 trial for advanced colorectal cancer

Recruitment complete in Aeterna Zentaris' perifosine Phase 3 trial for advanced colorectal cancer

CLEOPATRA Phase III study on HER2-positive mBC meets primary endpoint

CLEOPATRA Phase III study on HER2-positive mBC meets primary endpoint

EPO grants patent for Aeterna Zentaris' perifosine to treat benign, malignant tumours

EPO grants patent for Aeterna Zentaris' perifosine to treat benign, malignant tumours

Study finds link between genetic variation and cetuximab rectal cancer therapy

Study finds link between genetic variation and cetuximab rectal cancer therapy

Positive results from Nexavar Phase 2b trial on breast cancer presented at ASCO

Positive results from Nexavar Phase 2b trial on breast cancer presented at ASCO

Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011

Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011

Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011

Bayer, Onyx to present Nexavar-chemotherapy combination Phase 2b trial data in breast cancer at ASCO 2011

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer

ImmunID, Centre Léon Bérard and Cytheris commence CYT107-XELODA Phase IIa trial in metastatic breast cancer